Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The company reported ongoing enrollment in clinical trials at 4 billion cell dose levels and secured FDA agreement for outpatient dosing of NKX019, enabling treatment in community rheumatology centers and expanding patient access.